INVESTIGATOR SIGNATURE PAGE

Principal Investigator {Name} {Address} (if different from site)
Investigational Site {Site Name} {Address} I have read this protocol and agree to conduct this study in accordance with all stipulations of the protocol and in compliance with all applicable Good Clinical Practices and regulations.
Signature of Principal Investigator Date
Protocol Number: CAS-LIBHIVACC Version: 2. 
Proposed Intended Use
The BD FACSLyric flow cytometers (3-1, 4-2, 4-2-2 and 4-3-3 configurations) function as part of a system with BD FACSuite Clinical software intended for use with cleared or approved in vitro diagnostic (IVD) assays that are indicated for use with the instrument for identification and enumeration of human cell subsets. Only six fluorescence detection channels and two scatter channels using a blue (488 nm) and a red (633 nm) laser are cleared for in vitro diagnostic use. The predicate system will be the FACSCanto II flow cytometer/ FACSLoader (optional)/ FACSCanto Clinical software/FACS 7-Color Setup Beads.
Explanation of Sub-Studies
In addition, the protocol integrates an assessment of inter-laboratory reproducibility and an assessment of the customer's experience with the IUO BD FACSLyric system (usability).
In instances when information pertains to only one of the Sub-Studies, the information will be presented in parallel columns, as demonstrated above.
A table in the Appendix summarizes the study design of both Sub-Studies (section 18.1). A table in section 18.2 lists the instruments, controls, and reagents used in each Sub-Study.
Investigational Device System and Description
The investigational device system will be labeled for "Investigational Use Only (IUO)"/for "Performance Evaluation Only" (PEO) to satisfy FDA and IVDD requirements for products that are not cleared/approved. In this document, "IUO" will be used across the document to indicate the test product(s). The IUO system will consist of the following: 
IUO set-up beads:
 IUO BD CS&T beads  IUO BD FC beads (7-Color Kit for BD FACSuite)
The IUO BD FACSLyric flow cytometer has four configurations (3-1, 4-2, 4-2-2 and 4-3-3). The 4-3-3 configuration will be tested in clinical trials. This configuration has three lasers, two light scatter detectors, 10 fluorescence detectors with optical filters.
The IUO FACSuite Clinical software, which runs on a companion workstation, is an integrated suite of applications and utilities that will enable clinical laboratories to easily run automatic setup and clinical assays using the IUO BD FACSLyric flow cytometer.
IUO BD CS&T beads and IUO BD FC (Fluorescence Control) beads are intended for use with IUO BD FACSLyric and IUO FACSuite Clinical software. The IUO BD CS&T beads are used to check cytometer performance and automatically make adjustments. They are run daily for the Performance QC and twice-a-year for characterization QC. The IUO BD FC beads allow the software to determine and automatically update spillover values for fluorescent compensation for clinical assays. They are run monthly.
Predicate Device System
The predicate device system, IVD controls, and IVD reagents for the indicated Sub-Study consist of the following:
Instrument related: 
OBJECTIVES
Primary Objectives
Determine the method comparison between the investigational use only (IUO) BD FACSLyric system and the predicate IVD BD FACSCanto II system on the determination of lymphocyte sub-populations using Protocol Number: CAS-LIBHIVACC Version: 2.0 Date: 19Aug2016 IVD BD Multitest 6-color TBNK and BD Multitest IMK assay reagents with Trucount tubes with remnant, de-linked patient specimens at a minimum of three external study sites.
Secondary Objectives
 Assess inter-laboratory reproducibility at a minimum of three test sites.  Evaluate the customer's ease of use (usability) of the IUO BD FACSLyric system.
STUDY DESIGN
Overall Study Design
This is a multicenter, prospective evaluation of the IUO BD FACSLyric flow cytometer system vs. a predicate flow cytometer system at three or more clinical sites. This protocol contains two Sub-Studies (A and B), and each Sub-Study has a different predicate flow cytometer and different reagents, as shown above. Each Sub-Study requires at least 240 remnant specimens from patients exhibiting leucopenia or leukocytosis, or subjects free of hematological abnormalities (normal patients/donors), or HIV patients or patients undergoing immune reconstitution, in order to satisfy AbsCD4 and %CD4 binning requirements. For testing of Trucount Control reagents, each day of testing requires a remnant specimen from a patient free of hematological abnormalities (normal patient/donor).
Remnant specimens will be de-identified and delinked prior to enrollment into the study. If quantities and time are sufficient, specimens may be enrolled in both Sub-Studies.
For inter-laboratory reproducibility testing, three replicates of each level control material will be tested during two runs per day on the IUO BD FACSLyric for a minimum of five non-consecutive days at three clinical sites, with a minimum of one operator per site and minimum three instruments between all sites.
For usability evaluation, operators that are proficient with the investigational system will provide qualitative evaluation of the ease of use of the IUO BD FACSLyric system.
Specification of Study Endpoints
Primary Endpoints
For the Multitest reagents, the Method Comparison endpoints are the bias (expected difference) between the investigational system versus the predicate system measured as absolute lymphocytes subset counts and percentage of the lymphocyte sub-population.
Subsets:
Multitest IMK kit reagent: AbsCD3, AbsCD4, AbsCD8, AbsCD16+CD56, AbsCD19, %CD3, %CD4, %CD8, %CD16+CD56, %CD19. AbsCD3 and %CD3 will be determined by averaging the value obtained from tubes for reagents A and B for the same replicate.
Multitest 6-color TBNK reagent: AbsCD3, AbsCD4, AbsCD8, AbsCD16+CD56, AbsCD19, %CD3, %CD4, %CD8, %CD16+CD56, %CD19.
For each Sub-Study, remnant and de-identified patient specimens will be enrolled to satisfy AbsCD4 and %CD4 binning requirements, as indicated in Section 4.0.  Usability: Determination of the customer's qualitative assessment of how easily and safely an operator could use the IUO BD FACSLyric system.
3.2.3
Safety Endpoints During study testing, occurrence and severity of any adverse events will be evaluated, recorded, and followed up as required by BD procedures (Corporate Clinical Development and BD Biosciences).
Treatment Allocation and Methods to Reduce Bias
3.3.1 Randomization Remnant patient specimens will be de-identified and delinked from patient protected health information and assigned a Study ID number prior to enrollment in the study.
Skill and Behavior of Persons Interacting with the Device (if applicable)
The operators at each site conducting the study should be qualified and have experience with flow cytometric testing, including identifying appropriate specimens, staining samples, acquire data on a flow cytometer, and analyzing flow cytometry results.
Stopping Rules
No stopping rules for the study have been developed by the Sponsor. The Principal Investigator is responsible for suspending study enrollment for reasons of subject/clinician safety and well-being.
4.0
STUDY POPULATION The study will be conducted at high volume reference laboratories specializing in flow cytometric immunophenotyping. Study sites will obtain remnant specimens from patients exhibiting leucopenia or leukocytosis, or subjects free of hematological abnormalities (normal patients/donors), or HIV patients or patients undergoing immune reconstitution.
Specimens must be obtained with sufficient time to enroll and stain the specimen from time of blood draw. These specimens will be de-linked and enrolled for study testing.
Bins are designed to ensure that the samples will cover the reportable range. For each reagent, evaluable specimens will be enrolled to satisfy AbsCD4 and %CD4 binning requirements, as indicated in the chart below, based on the average value obtained from the two replicates acquired on the predicate instrument. It is expected that each site will enroll a minimum of 60 specimens with evaluable results per assay, for a minimum total of 240 specimens with valid results across at least three clinical sites. 2) 20% ≤ CD4% < 35% 80 50
3) 35% ≤ CD4% < 100% 80 50
In order to fill bins, up to 15% of specimens with evaluable results within each bin may be manipulated. Manipulation must follow an approved method.
Unless specified otherwise, these criteria apply at screening and throughout the study.
Inclusion Criteria
Peripheral whole blood specimens must satisfy all of the following conditions to be considered for participation:
a. Leftover (i.e., residual) and has not been prospectively procured for study enrollment, but has been collected and tested for CD4 counts and any remaining specimen would routinely be discarded 
Ancillary Products
Ancillary products are materials that are critical to the use of the study product or execution of the protocol, such as certain concomitant medications or critical device components which are used with the study device and must be used exactly as specified in this protocol.
BD will provide the following as needed:
 Electronic pipette(s) (BD Catalogue # 646539 or similar)  External Hard Drives, USB drives, CDs, or DVDs (to store study data)
Site should have access to the following: 
Product Labeling
Investigational products (including marketed products used off-label) and units shall be labeled in accordance with regulatory requirements, including the following statement, "For Investigational Use Only. The performance characteristics of this product have not been established." Or "For Performance Evaluation Only" (PEO).
For investigational products, labeling will also include the following at minimum, when applicable:  Study Number  Product Identification (Product name, catalog number, instrument plate, etc.)  Manufacturer name and location  Batch/Lot #  Use by/Expiration Date Commercial products will be supplied as labeled by the manufacturer.
Maintenance and Storage of Study Products
The IUO BD FACSLyric, IVD BD FACSCanto II along with associated workstations and software, should be stored at 16-29˚C. Flow cytometers should be up-to-date on regular maintenance.
BD FACSLysing Solution and BD FACSFlow sheath fluid should be stored at 16-29˚C. BD Trucount Tubes should be stored at 2-25˚C. Unless otherwise indicated, all other controls and reagents should be stored at 2-8˚C. No study product shall be used beyond its expiration date. (Perform testing twice per day of testing for at least 5 non-consecutive days.)  Stain and acquire study samples.
o BD Multitest 6-color TBNK and BD Multitest IMK stained samples from a study specimen should be acquired together.  Review and analyze study specimen data. Store data on site and provide to BD.
Specimen Enrollment
BD Multitest and BD testing requires remnant EDTA specimens with sufficient quantity from patients exhibiting leucopenia or leukocytosis, or subjects free of hematological abnormalities (normal patients/donors), or HIV patients or patients undergoing immune reconstitution, For all specimens,  Confirm that specimen meets inclusion and exclusion criteria.  De-identify specimen and assign a Study ID number. The site will maintain a coded list that associate the specimen identity with the Study ID number. This list will not be transferred to the sponsor.
Instrument Setup and Process Control
The steps for Instrument Setup are depicted in 
Inter-Laboratory Reproducibility: Sample Staining and Acquisition
Inter-laboratory reproducibility will be performed twice per day for a minimum of five non-consecutive days at three or more clinical study sites. Each day will include two runs of three replicates from a specific lot of ILR specimens. All clinical study sites will use the same lot of testing material. At least five nonconsecutive days of evaluable data is required. Sites may need to capture data on additional days in order to meet this minimum. The steps for Inter-Laboratory Reproducibility testing are depicted in Figure 3 .  Acquire stained controls on the IUO BD FACSLyric after setup and process controls, and within the age of stain indicated for the assay.
Sample Staining and Acquisition
Initially, an enrolled specimen should have enough volume to be used for the study. As CD4 bins are filled for each Sub-Study, sponsor will inform site that testing is no longer necessary for specific assay or SubStudy. The steps for Method Comparison testing are depicted in If there is an issue with the data acquisition of a tube, rerun the tube. If there is still an issue, stain a new tube and acquire data from it. Appropriate CRF(s) must be completed.
Data Review and Analysis
 After data acquisition, all data from the investigational and predicate instruments should be reviewed and gates adjusted, as necessary. Store electronically or print all reports. Export CSV files.
 Review documentation and prepare data packet, to include electronic instrument data files, PDFs, completed CRFs, etc.
Protocol Number: CAS-LIBHIVACC Version: 2.0 Date: 19Aug2016  Store data on provided electronic devices and in data binders.
 For submission of data to BD, print outs and CRFs will be scanned into electronic files. Provide data package to BD using the BD format transfer protocol (FTP) site or, if required, by mail.
Required Training and Proficiency Testing
All study staff participating in the study will be trained in the study design and study procedures. Training will be documented. Each operator must also pass proficiency evaluation. Proficiency testing will involve performing the study workflow, including instrument startup, processing and running of controls and specimens, completing all appropriate paperwork, and submission of data. The data will be compared to expected criteria, and paperwork (CRFs, etc.) will be evaluated, for determination of the operator passing. Instructions for proficiency testing will be provided prior to study execution.
Customer Ease of Use/Usability
The IUO BD FACSLyric System will be evaluated after the operator(s) at the site(s) have completed Proficiency Training and before the start of enrollment. The operators will complete and return the Eases of Use survey to BD.
 Ease of use survey will consist of questions addressing workflow and functionality of the IUO BD FACSLyric System. Each question will have 6 possible answers with a numeric value assigned for analysis. Example of the answers as the following: o Extremely easy/satisfied, numeric value = 5 o Somewhat easy/satisfied, numeric value = 4 o Neutral, numeric value = 3 o Slightly difficult/dissatisfied, numeric value = 2 o Very difficult/dissatisfied, numeric value = 1 o Not applicable (NA), numeric value = 0 6.9 Additional Site Responsibilities 6.9.1 IUO BD FACSLyric Monthly Maintenance The site will be responsible for normal monthly maintenance of the IUO BD FACSLyric flow cytometer. On a monthly basis, the "monthly clean procedure" needs to be performed. Instructions are in the Instructions for Use. Documentation of cleaning needs to be sent to BD. Also, BD FC beads need to be run every month to set compensation controls in order for study data to be evaluable. Documentation of running the BD FC beads needs to be sent to BD.
6.9.2
Predicate Instrument Maintenance Instruments should be cleaned on a monthly basis or as indicated in site protocols.
6.9.3
Communication with BD As necessary, the site will be required to respond to DCFs and other study related questions in a timely fashion. Delay in responding could result in data being considered non-evaluable.
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INTERRUPTION OR DISCONTINUATION OF PARTICIPATION/TESTING
Discontinuation of Specimen Testing
Post-enrollment, instances may occur that will require the discontinuation of the specimen testing such as:  If further visual inspection of an enrolled specimen reveals clotting and/or hemolysis that was not initially apparent, this specimen would be unsuitable for study testing or, if results have been generated, these results would not be included in analysis.  If an enrolled specimen (of sufficient quantity) is broken/spilled, this "quantity not sufficient (QNS)" specimen would require discontinuation of study testing.  If an enrolled specimen (with adequate time post-draw to enroll for study testing) cannot be stained within the allotted time due to unanticipated testing difficulties, this specimen would require discontinuation of study testing. The decision to discontinue testing of a specimen can be made for each Sub-Study.
7.1.1
Replacement of Discontinued Subjects/Specimens Discontinued samples will be replaced by additional enrolled specimens.
7.1.2
Retention of Data from Discontinued Subjects/Specimens No data will be collected from subjects/specimens after the point of discontinuation except as needed to follow ongoing adverse events. All study data collected from the subject up to the point of discontinuation will be recorded on the Case Report Form, entered into the study database, and included in subsequent analyses, as appropriate.
RISK / BENEFIT ASSESSMENT
Potential Risks
Sites will use only remnant specimens for the execution of this protocol. Therefore there are no risks to the patient/subject. In addition, the results produced for this study:
• Will not be used for diagnosis or treatment of the patient/subject;
• Will include parallel testing by an approved and established method.
To reduce the likelihood of any risks to site staff participating in this investigation, all processing, and testing of potentially infectious Specimens must always be performed according to Standard Precautions, CDC Guidelines, Standard Guidelines, and the participating sites' standard operating procedures and policies.
Potential Benefits
There are no direct benefits to the subject for participation in this study.
ASSESSMENT OF SAFETY AND ADVERSE EVENTS
This study is being conducted with remnant specimens and does not include any human subjects. Refer to Study Incidents (section 10.0) for procedures in the event of injury to study site personnel.
Protocol Number: CAS-LIBHIVACC Version: 2.0 Date: 19Aug2016 10.0 INCIDENTS A Clinical Study Incident is defined as any problem or issue involving the investigational product(s), reference methods, associated procedures or equipment, or represents a product-related injury (or potential for injury) to study subjects or personnel as a result of execution of this protocol. Clinical Study Incidents may adversely (or potentially adversely) affect human safety, the integrity of the evaluation data, or the operation of devices or systems, and warrant prompt attention.
Examples of Clinical Study Incidents that are not Adverse Events might be mislabeling or adulteration of the investigational device, equipment or device malfunctions, errors in the device instructions, damage to devices caused by shipping or handling or improper storage, or injury to study personnel due to execution of the protocol. If appropriate, an Incident may also be documented and reported as a protocol deviation. Study-specific procedures for reporting Incidents, as well as adverse events and protocol deviations, will be provided to the study site prior to study execution. The Monitor should be contacted immediately when site becomes aware of or suspects any defective or malfunctioning product. This includes:
• Products that are involved in Study Incidents,
• Products that are found to be expired, damaged or defective,
• Products that are possibly the cause of an adverse effect, regardless of whether the product was believed to be damaged, defective or malfunctioning.
Such products (whether investigational or marketed) should be segregated and returned with appropriate documentation to the BD address below, unless instructed otherwise by BD. The Study Monitor should be contacted with any questions regarding return of study products. BD will supply mailing kits specifically intended for product contaminated with potentially bio-hazardous material.
RETURN OR DESTRUCTION OF STUDY PRODUCT
All disposable, used products not failed, damaged or otherwise involved in an Incident or Adverse Event are to be discarded into appropriate waste containers at the investigational site.
Unless instructed otherwise by BD, the Investigator will return all remaining unused or unopened test, reference, and ancillary study products to BD. At the conclusion of the study, and as appropriate during the course of the study, any products, supplies or BD equipment that are required to be returned will be shipped to BD at the address below, unless instructed otherwise: 
Source Documents
Source data includes all information in original records (and certified copies of original records) of clinical findings, observations, or other activities (in a clinical study) used for the reconstruction and evaluation of the study. Source data are contained in source documents (original records or certified copies) and are used to verify the authenticity of information recorded on the Case Report Form (CRF). Typical source Protocol Number: CAS-LIBHIVACC Version: 2.0 Date: 19Aug2016 documents include the hospital chart, medical office file, laboratory report, clinician notes, patient record, recorded data from automated instruments or other documentation prepared and maintained by the investigator/staff or ancillary services which contains a record of all observations and other data pertinent to the investigation on a study subject.
The investigator is required to maintain original source documents at the site. Should an original source document (e.g., an instrument printout, direct entry CRF) need to be forwarded to BD for data entry, the site must retain a clearly designated certified copy. The Study Monitor will confirm that procedures for copy certification have been established at the site prior to transmittal of any original source documents.
12.2
Case Report Forms (CRF) The case report forms (CRF) will be provided by the Sponsor. The term "CRF" as used in this protocol may refer to traditional paper CRFs, or electronic case report forms for electronic data capture (EDC), as determined by the Sponsor.
The Investigator may delegate CRF completion to study personnel. However, the Sponsor must be apprised in writing of the name of such persons and the scope of their authority. The Principal Investigator or designee is obligated to review each CRF page and sign or initial the indicated pages using ink or for EDC, an electronic signature.
All entries to a paper CRF should be made clearly in black or dark blue indelible ballpoint pen to ensure the legibility of self-copying or photocopied pages. Corrections are made by placing a single horizontal line through the incorrect entry, so that the original entry can still be seen, and placing the revised entry beside it. The revised entry must be initialed and dated by a member of the Investigator's research team authorized to make CRF entries. Correction fluid must not be used. CRF entries will be compared to source documents by the study monitor or designated personnel. Unless specified otherwise, all information on the CRFs must be traceable to original source documents.
12.2.1
CRF as Source Document Some study data will be collected directly on CRFs and there will be no matching source from which to verify the entry. As a result, these CRFs serve as original source documents.
12.2.2
CRF/Data Transmittal CRF and other data should be transmitted to the sponsor within one week of the testing date. Instructions for CRF and Data Transmittal will be provided to the Investigator at Study Initiation. Specific procedures may be described in a study-specific Monitoring Plan.
12.3
Electronic Source Data (optional) Electronic files generated from study instruments contain source data. The site must maintain electronic files of all these data on storage devices (CDs, USB drives, etc.) provided by the Sponsor. Some electronic source data will need to be transmitted to the Sponsor within one week of the testing date. Instructions for Data Transmittal will be provided to the Investigator at Study Initiation Specific procedures will be described in a study-specific Data Management Plan.
12.4
Data Management and Storage Data Management will be performed by the Sponsor. Data from completed CRFs will be entered into a controlled database and the database verified for accuracy against the CRFs, when applicable. If electronic data capture is utilized, the electronic records entered at the site will be entered directly into the controlled Protocol Number: CAS-LIBHIVACC Version: 2.0 Date: 19Aug2016 database. Data security is ensured through password protection, limited access, audit trails, and regular backups of the data. Upon completion of the study and verification of data, data will be screened for accuracy and completeness, after which the database will be locked from any additional changes. A copy of the locked database will be provided to the BD Corporate Statistics Department for statistical analysis.
STATISTICAL METHODS
13.1
Sample Size Determination For Method Comparison study, each Sub-Study will have a minimum sample size of 240 evaluable specimens across all sites that provide valid results to determine the bias (expected difference) between the investigational system versus the predicate system.
Inter-Laboratory Reproducibility evaluation and analysis are based on the CLSI guideline EP05-A3 2 . In line with guidance from this document, evaluable data will be collected from 3 sites for a minimum of 5 non-consecutive days, 2 runs of 3 replicates on each day.
13.2
Data Evaluability Data will be considered Evaluable if all the following is met:
 Adequate controls have been run and are acceptable.  Data has been produced from testing of an evaluable specimen (has met inclusion and exclusion criteria).  Specimen testing has occurred within the allotted time for the assay (Age of Stain).  Results are within the reportable range of the assay.  Data packets are complete and all forms are complete.  Documentation is complete.
Discrepancies in source documents can result in the data being considered non-evaluable.
Statistical Methods
General Statistical Considerations
All statistical analyses will be performed using commercially available statistical software. Adequate source document verification and/or audit activities will be utilized to assure the validity of performance evaluation conclusions. Analysis shall be performed based on methods described in the Statistical Analysis Plan. All related and resulting reports, documents and data shall be produced and maintained in such a way as to ensure their control and the protection of subject privacy as far as is reasonably practicable. Data files and analytic reports will be archived according to requisite regulatory standards.
Method Comparison Statistical Methods
Evaluation of data will follow CLSI guideline EP09-A3 3 .
Estimates from the Deming regression will be used to evaluate the equivalency between the investigational and predicate systems of the following parameters:
AbsCD3, AbsCD4, AbsCD8, AbsCD19, AbsCD16+CD56, %CD3, %CD4, %CD8, %CD19, %CD16+CD56.
(For Multitest IMK kit, AbsCD3 and %CD3 values from tubes for reagents A and B will be averaged.)
The Investigator is responsible for ensuring that any site-owned equipment required for use in the study is properly installed and maintained (e.g., inspected, calibrated, alarmed). Documentation of equipment maintenance procedures must be available for review by the Monitor.
14.3
Audits and Inspections If the study is selected for audit by the Sponsor or if there is an inspection by the appropriate Health Authorities, then the Investigator and his team will make themselves available during the visit. The Investigator must agree to the inspection of all study related records and give the auditor/inspector direct access to source documents for verification of data on CRFs. The subject's anonymity must be safeguarded and data checked during the audit remain confidential.
As soon as the Investigator is aware of an upcoming inspection/audit by the Health Authorities, he/she will promptly inform BD. As agreed with the Investigator, BD personnel may be present at the site during the inspection.
14.4
Protocol Deviations Protocol deviations are not permitted and should be implemented prospectively as a protocol amendment whenever practical or appropriate, unless required to protect the safety and well-being of the subject. The Investigator must notify the Sponsor immediately of any such deviation resulting from the need to protect a subject. Protocol deviations (other than those required to protect the safety and well-being of a subject) may impact the evaluability of study data, and may place subjects at risk. If the Investigator or their staff inadvertently deviates from the study plan, the Investigator should implement appropriate corrective and preventive procedures, and should notify the Sponsor at their earliest convenience. Significant deviations may also need to be reported to the IRB/EC and local health authority. The Study Monitor will evaluate records of study conduct at the site to identify any deviations, and will also report them to the Sponsor. Upon evaluation by the Sponsor, actions may be required to prevent additional deviations, such as retraining of the site, implementation of additional site procedures, and more frequent monitoring. If these steps fail, more serious measures, up to and including termination of the site and withdrawal of study product may be necessary.
ETHICAL AND REGULATORY STANDARDS
15.1 IRB/EC An appropriate IRB/EC must review this protocol, the Informed Consent Form (if applicable), and any other supporting study documents which affect subject or study personnel safety, prior to study initiation at an investigational site. No investigational site may begin the study until the IRB/EC has given its written approval, signed by the IRB/EC chairperson or authorized personnel, and a copy of the approval letter and the approved Informed Consent Form (if applicable) has been provided to the Sponsor.
15.2
Informed Consent For Primary Objective: Only leftover de-identified/de-linked specimens from routine laboratory testing will be enrolled in the study and all subject's personal health information will be removed prior to enrollment. Therefore, Informed Consent may not be required by the IRB/EC. For Secondary Objective:
Protocol Number: CAS-LIBHIVACC Version: 2.0 Date: 19Aug2016 Informed consent is not applicable for this study, as only commercial control materials are used for testing.
15.3
Confidentiality of Data Subject confidentiality is strictly held in trust by the participating investigators, their staff, and BD and their agents. This confidentiality is extended to cover testing of biological samples in addition to the clinical information relating to participating subjects. Subject confidentiality and anonymity will be maintained at all times by removal of all identifiers from any data, clinical samples or documentation submitted for this study.
Any data collected meeting the definition of PHI will be collected and maintained using the designated authorizations and following all privacy procedures as specified in the applicable health authority regulations.
BD will maintain the security and confidentiality of all clinical study data sent to BD. BD clinical study databases will not be shared with any third party without the express written consent of the Principal Investigator and/or Site.
The Study Monitor or other authorized representatives of BD may inspect all documents and records required to be maintained by the Investigator. The Site will permit access to such records. BD and the Site may be required to provide regulatory agencies access to clinical study data and records, as well as source documents.
All other agreements as to confidentiality by BD, the Principal Investigator, and the Site may be found in the Confidential Disclosure Agreement and the Clinical Trial Agreement.
15.3.1
De-identification of Remnant Specimens Personal information will be maintained confidential in accordance with the site's procedures and the Health Insurance Portability and Accountability Act (HIPAA) (if applicable). Donors/specimens will be assigned a coded identification number according to the site policy for delinked specimens. The coded list will remain with the clinical site or principal investigator or the site-specific policy will be followed.
For in vitro diagnostic device studies using leftover specimens, the FDA Guidance on Informed Consent for In Vitro Diagnostic Device Studies Using Leftover Human Specimens must be followed when Informed Consent is not obtained. The specimens must be provided to the investigator(s) without identifiers and the supplier of the specimens must have established policies and procedures to prevent the release of personal information.
15.4
Protocol Modifications Amendments to the protocol will not be implemented without agreement from the Sponsor and prior submission to and written approval from the governing IRB/EC, except when necessary to eliminate an immediate hazard to the subject. Notice of an emergency modification shall be given to the Sponsor and the reviewing IRB/EC as soon as possible, but in no event later than 5 working days after the emergency occurred. Protocol amendments may affect Informed Consent Forms for current and future subjects. Minor changes to the protocol, such as correction of typographical errors or changes in personnel names (other than the PI) or contact information will be processed as administrative changes. Administrative changes will be submitted to the governing IRB/EC but implementation of the administrative change may proceed without prior IRB/EC approval, unless so required by the IRB/EC or site SOPs.
15.5
Study Discontinuation BD reserves the right to temporarily suspend or prematurely discontinue the study at a single site or at all sites at any time and for any reason. If such action is taken, BD will discuss the reasons with all Investigators (the Investigator). If the study is terminated or suspended due to safety reasons, the sponsor will inform the health authorities as required, and provide the reason(s) for the action. Investigator(s) must inform their IRB/EC promptly and provide the reason(s) for the suspension or termination.
15.6
Clinical Study Registration In compliance with Title VIII of Public Law 110-85, known as FDA Amendments Act of 2007 (FDAAA), BD will register all applicable studies and disclose study results in a publicly accessible database, e.g. the ClinicalTrials.gov web site. Applicable studies will be registered no later than 21 days after commencing enrollment. Study results for applicable studies will be posted to the website within 12 months of the last subject visit for collection of primary outcome data, or after health authority approval for previously unapproved devices. BD has responsibility for determining whether this study qualifies as an "applicable" study under the law, and if so, will take responsibility for registration and disclosure as required by law.
15.7
Publication of Results BD believes that results of applicable clinical studies of our products should be published in peer-reviewed literature in a timely, accurate, complete and balanced manner, regardless of study outcomes. BD is committed to making information public whenever it relates to the safety and efficacy of its marketed products. Should this study be considered an "applicable study," any formal presentation or publication of data collected from this study will be considered as a joint publication by the investigator(s) and the appropriate personnel of BD. Authorship will be based on generally accepted criteria of the ICMJE (International Committee of Medical Journal Editors) and determined by mutual agreement. For multi-center studies, it is mandatory that the first publication is based on data from all centers, analyzed as stipulated in the protocol by BD statisticians, and not based on data from single sites or a subset of sites. Investigators participating in multi-center studies agree not to present data gathered from one center or a small group of centers before the full, initial publication, unless formally agreed to by all other investigators and BD (the sole exception being an unanticipated adverse event that is product-related and which might have clinically significant safety implications for a marketed product or a class of products). BD must receive copies of any intended communication in advance of publication as specified in the Clinical Study Agreement. In a timely manner, BD will review the communications for accuracy (thus avoiding potential discrepancies with submissions to health authorities), verify that confidential information is not being inadvertently divulged and to provide any relevant supplementary information to the investigators.
15.8
Record Retention If the Principal Investigator or Clinical Center withdraws from the responsibility of keeping the study records, custody must be transferred to a person or entity who will accept the responsibility. BD must be notified in writing of the name and address of the new custodian. Federal regulations require that a copy of all essential study documents (e.g., IRB/EC approvals, signed informed consent forms, source documents, CRF copies, safety reports, test article dispensing records, etc.), must be retained in the files of the responsible Investigator for a minimum of 2 years following notification Protocol Number: CAS-LIBHIVACC Version: 2.0 Date: 19Aug2016
